S-1 as first-line treatment for advanced gastric cancer

Abstract

JIANG Feng-E, SUN Ping. S-1 as first-line treatment for advanced gastric cancer[J]. Journal of International Oncology, 2014, 41(3): 211-213.

［1］吴春晓，郑莹，鲍萍萍，等. 上海市胃癌发病流行现况与时间趋势分析［J］. 外科理论与实践, 2008, 13(1):2429. ［2］ Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S1 in metastatic gastric cancer: a randomised phase 3 study［J］. Lancet Oncol, 2009, 10(11):10631069. ［3］ Imamura H, Kishimoto T, Takiuchi H, et al. Phase II study of S1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404)［J］. J Chemother, 2013, 15(8):13361341. ［4］ Koizumi W, Narahara H, Hara T, et al. S1 plus cisplatin versus S1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial［J］. Lancet Oncol, 2008, 9(3):215221. ［5］ Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial［J］. J Clin Oncol, 2010, 28(9):15471553. ［6］ Ajani JA, Buyse M, Lichinitser M. Combination of cisplatin/S1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5fluorouracil in the FirstLine Advanced Gastric Cancer Study［J］. Eur J Cancer, 2013, 49(17):36163624. ［7］ Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S1 as firstline treatment for advanced gastric cancer (GSOX study)［J］. Ann Oncol, 2010, 21(5):10011005. ［8］ Yang L, Song Y, Zhou AP, et al. A phase Ⅱ trial of oxaliplatin plus S1 as a firstline chemotherapy for patients with advanced gastric cancer［J］. Chin Med J(Engl), 2013, 126(18): 34703474. ［9］ Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S1oxaliplatin versus capecitabineoxaliplatin in advanced gastric cancer［J］. Eur J Cancer, 2012, 48(4):518526. ［10］ Shuichi Hironaka, Kentaro Yamazaki, Keisei Taku, et al. Phase I Study of Docetaxel, Cisplatin and S1 in Patients with Advanced Gastric Cancer［J］. Jpn J Clin Oncol, 2010, 40(11):10141020. ［11］ Kunisaki C, Takahashi M, Makino H, et al. Phase Ⅱ study of biweekly docetaxel and S1 combination chemotherapy as firstline treatment for advanced gastric cancer［J］. Cancer Chemother Pharmacol, 2011, 67(6): 13631368. ［12］ Cui Y, Li Q, Yu Y, Chen Y, et al. Combination of lowdose docetaxel and standarddose S1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor［J］. Cancer Chemother Pharmacol, 2013, 71(1):145152. ［13］ Kunisaki C, Takahashi M, Ono HA, et al. Biweekly Docetaxel and S1 combination chemotherapy as firstline treatment for elderly patients with advanced gastric cancer［J］. Anticancer Res, 2013, 33(2):697704. ［14］ Narahara H, Ishii H, Imamura H, et al. Randomized phase Ⅲ study comparing the efficacy and safety of irinotecan plus S1 with S1 alone as firstline treatment for advanced gastric cancer (study GC0301/TOP002)［J］. Gastric Cancer, 2011, 14(1):7280. ［15］ Park SR, Kong SY, Rhee J, et al. Phase Ⅱ study of a triplet regimen of S1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results［J］. Ann Oncol， 2011, 22(4):890896.

[1]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[4]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492.
[9]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341.
[10]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[13]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185.
[14]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.
[15]	Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86.

S-1 as first-line treatment for advanced gastric cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments